13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839948
Total reported value
$4.2B
$4.2B
38 檔
7.2%
At the close of Q2 2025, TCG Crossover Management, LLC disclosed equity holdings valued at approximately $4.2B, spread across 38 reported holdings.
TCG Crossover Management, LLC executed strategic sector rebalancing during Q2 2025, establishing 5 new positions while fully exiting 5 holdings and trimming 3 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | Stock-Other | 10.90% | -0.84% | — | |
| 2 | TNGX | Tango Therapeutics Inc | Stock-Other | 6.28% | +0.52% | — | |
| 3 | COGT | Cogent Biosciences Inc | Stock-Other | 5.71% | -0.93% | — | |
| 4 | OCUL | Ocular Therapeutix Inc | Stock-Other | 5.64% | -0.01% | — | |
| 5 | CDTX | Cidara Therapeutics Inc | Stock-Other | 5.60% | — | — | |
| 6 | ABVX | Abivax Sa-adr | Stock-Other | 5.29% | -1.41% | — | |
| 7 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 4.35% | +0.22% | — | |
| 8 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 4.34% | -4.87% | EXIT | |
| 9 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 4.13% | -1.15% | EXIT | |
| 10 | DYN | Dyne Therapeutics Inc | Stock-Other | 4.10% | +0.07% | +42.13% | |
| 11 | EYPT | Eyepoint Inc | Stock-Other | 3.84% | — | — | |
| 12 | UPB | Upstream Bio Inc | Stock-Other | 3.51% | -0.05% | EXIT | |
| 13 | SVRA | Savara Inc | Stock-Other | 3.22% | -0.10% | — | |
| 14 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 3.20% | -0.10% | — | |
| 15 | TYRA | Tyra Biosciences Inc | Stock-Other | 3.17% | -1.07% | — | |
| 16 | IRON | Disc Medicine Inc | Stock-Other | 2.81% | -0.09% | — | |
| 17 | TRML | Tourmaline Bio Inc | Stock-Other | 2.70% | — | — | |
| 18 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 2.65% | — | — | |
| 19 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.52% | -0.19% | EXIT | |
| 20 | XNCR | Xencor Inc | Stock-Other | 2.20% | +0.10% | — | |
| 21 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 2.01% | +0.34% | — | |
| 22 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.78% | — | -32.27% | |
| 23 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.69% | — | — | |
| 24 | RAPT | Rapt Therapeutics Inc | Stock-Other | 1.50% | — | — | |
| 25 | ✓ | Third Harmonic Bio Inc | Stock-Other | 1.19% | — | -23.55% | |
| 26 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.14% | — | — | |
| 27 | MBX | Mbx Biosciences Inc | Stock-Other | 0.85% | +0.30% | — | |
| 28 | NKTR | Nektar Therapeutics | Stock-Other | 0.79% | — | — | |
| 29 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.61% | -0.04% | EXIT | |
| 30 | KOD | Kodiak Sciences Inc | Stock-Other | 0.49% | -0.23% | — | |
| 31 | KURA | Kura Oncology Inc | Stock-Other | 0.48% | — | -48.36% | |
| 32 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.45% | -0.64% | — | |
| 33 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 0.44% | — | — | |
| 34 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.28% | +1.02% | — | |
| 35 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.08% | — | — | |
| 36 | JBIO | Jade Biosciences Inc | Stock-Other | 0.07% | — | — | |
| 37 | CABA | Cabaletta Bio Inc | Stock-Other | 0.02% | — | — | |
| 38 | KROS | Keros Therapeutics Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | TNGX | Tango Therapeutics Inc | +4.3% | — | Unchanged |
| 2 | AGIO | Agios Pharmaceuticals Inc | +2.7% | NEW | New buy |
| 3 | CDTX | Cidara Therapeutics Inc | +2.6% | — | Unchanged |
| 4 | FULC | Fulcrum Therapeutics Inc | +2.1% | — | Unchanged |
| 5 | RAPT | Rapt Therapeutics Inc | +1.5% | NEW | New buy |
| 6 | AMLX | Amylyx Pharmaceuticals Inc | +1.5% | — | Unchanged |
| 7 | EYPT | Eyepoint Inc | +1.2% | — | Unchanged |
| 8 | UPB | Upstream Bio Inc | +1.2% | — | Unchanged |
| 9 | ELVN | Enliven Therapeutics Inc | +1.1% | NEW | New buy |
| 10 | SLN | Silence Therapeutics Plc-adr | +0.8% | — | Unchanged |
| 11 | NKTR | Nektar Therapeutics | +0.8% | NEW | New buy |
| 12 | OCUL | Ocular Therapeutix Inc | +0.3% | — | Unchanged |
| 13 | DYN | Dyne Therapeutics Inc | +0.3% | +42.13% | Add |
| 14 | MBX | Mbx Biosciences Inc | +0.2% | — | Unchanged |
| 15 | ABVX | Abivax Sa-adr | +0.1% | — | Unchanged |
| 16 | JBIO | Jade Biosciences Inc | +0.1% | NEW | New buy |
| 17 | KOD | Kodiak Sciences Inc | +0.1% | — | Unchanged |
| 18 | VTYXUSD | Ventyx Biosciences Inc | 0% | — | Unchanged |
| 19 | COGT | Cogent Biosciences Inc | 0% | — | Unchanged |
| 20 | GPCR | Structure Therapeutics Inc | 0% | — | Unchanged |
| 21 | ✓ | Third Harmonic Bio Inc | — | -23.55% | Trim |
| 22 | CABA | Cabaletta Bio Inc | — | — | Unchanged |
| 23 | KROS | Keros Therapeutics Inc | — | — | Unchanged |
| 24 | AVTX | Avalo Therapeutics Inc | -0.3% | — | Unchanged |
| 25 | TRDA | Entrada Therapeutics Inc | -0.3% | — | Unchanged |
| 26 | VTGN | Vistagen Therapeutics Inc | -0.3% | — | Unchanged |
| 27 | CATBUSD | Astria Therapeutics Inc | -0.3% | — | Unchanged |
| 28 | IRON | Disc Medicine Inc | -0.3% | — | Unchanged |
| 29 | NKTREUR | Nektar Therapeutics | -0.4% | EXIT | Sold out |
| 30 | TRML | Tourmaline Bio Inc | -0.4% | — | Unchanged |
| 31 | TYRA | Tyra Biosciences Inc | -0.5% | — | Unchanged |
| 32 | DNTH | Dianthus Therapeutics Inc | -0.5% | — | Unchanged |
| 33 | AVU0 | Adverum Biotechnologies Inc | -0.6% | — | Unchanged |
| 34 | ✓ | -0.8% | EXIT | Sold out | |
| 35 | KURA | Kura Oncology Inc | -0.8% | -48.36% | Trim |
| 36 | SLNOEUR | Soleno Therapeutics Inc | -0.9% | -32.27% | Trim |
| 37 | 260 | Centessa Pharmaceuticals-adr | -1.3% | — | Unchanged |
| 38 | XNCR | Xencor Inc | -1.4% | — | Unchanged |
| 39 | CGON | Cg Oncology Inc | -1.4% | — | Unchanged |
| 40 | SVRA | Savara Inc | -1.5% | — | Unchanged |
| 41 | CMPS | Compass Pathways PLC | -1.5% | EXIT | Sold out |
| 42 | ✓ | Rapt Therapeutics Inc | -2.2% | EXIT | Sold out |
| 43 | MLYS | Mineralys Therapeutics Inc | -5.4% | EXIT | Sold out |
According to official SEC Form 13F filings, TCG Crossover Management, LLC reported a total U.S. public equity portfolio value of $4.2B across 38 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CGON, TNGX, COGT) accounted for 7.2% of total reported equity market value during Q2 2025.
Top New Position Initiated
AGIO
市值: $23.2M
Top Position Liquidated / Trimmed
MLYS
前期市值: $39.2M
During Q2 2025, TCG Crossover Management, LLC's top holdings by market value included CGON (10.9%)、TNGX (6.3%)、COGT (5.7%). The largest single position, CGON, represented 10.9% of total portfolio value.
In Q2 2025, TCG Crossover Management, LLC made 14 total portfolio adjustments, initiating 5 new buys, adding to 1 positions, trimming 3 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.